Targets › NQO1
1 program from 1 company in 1 trial: 1 Phase 3; Neurology; next expected readout Dec 2027.
Flavin-containing quinone reductase that catalyzes two-electron reduction of quinones to hydroquinones using either NADH or NADPH as electron donors. In a ping-pong kinetic mechanism, the electrons are sequentially transferred from NAD(P)H to flavin cofactor and then from reduced flavin to the quinone, bypassing the formation of semiquinone and reactive oxygen species (By similarity). (UniProt, P15559)
Open in Phaseline: the race on NQO1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| PTC Therapeutics | Vatiquinone Quinone reductase 1 modulator | NQO1 | Phase 3 | Friedreich Ataxia | Dec 2027 |
Friedreich Ataxia (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.